Alteration of amino acid neurotransmitters in brain tissues of immature rats treated with realgar

Journal of Pharmaceutical and Biomedical Analysis

Volumn 57, Issue 1, 2012, Pages 120-124

  Huo, Taoguang ^a   Chang, Bei ^a   Zhang, Yinghua ^a   Chen, Zaixing ^a   Li, Weikai ^a   Jiang, Hong ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Amino acid neurotransmitter; Brain tissue; HPLC UV; Neurotoxicity; Realgar

Indexed keywords

4 AMINOBUTYRIC ACID; AMINO ACID; ASPARTIC ACID; CHINESE DRUG; GLUTAMIC ACID; GLUTAMINE; GLYCINE; HOMOCYSTEINE; NEUROTRANSMITTER; REALGAR; SERINE; TAURINE; UNCLASSIFIED DRUG;

AMINO ACID BRAIN LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; BRAIN TISSUE; CONCENTRATION RESPONSE; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LEARNING; MEMORY; NERVE CELL LESION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; ULTRAVIOLET RADIATION;

ANIMALS; ARSENICALS; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; NEUROTRANSMITTER AGENTS; RATS; SPECTROPHOTOMETRY, ULTRAVIOLET; SULFIDES;

EID: 80054036145     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.08.032     Document Type: Article

References (28)

1. Liu J., Lu Y., Wu Q., Goyer R.A., Waalkes M.P. Mineral arsenicals in traditional medicines: orpiment, realgar, and arsenolite. J. Pharmacol. Exp. Ther. 2008, 326:363-368.
2. Wei L., Liao P., Wu H., Li X., Pei F., Li W., Wu Y. Metabolic profiling studies on the toxicological effects of realgar in rats by (1)H NMR spectroscopy. Toxicol. Appl. Pharmacol. 2009, 234:314-325.
3. Zhang L., Gao S.H., Zhou C.F., Lin R.C., Liu C.H. Safety issues of traditional Chinese medical preparations containing arsenic substances: review starting from Niuhuang Jiedu Pian (Wan). Zhongguo Zhong Yao Za Zhi 2006, 31:2010-2013.
4. Liu J., Liang S.X., Lu Y.F., Miao J.W., Wu Q., Shi J.S. Realgar and realgar-containing Liu-Shen-Wan are less acutely toxic than arsenite and arsenate. J. Ethnopharmacol. 2011, 134:26-31.
5. Hall A.H. Chronic arsenic poisoning. Toxicol. Lett. 2002, 128:69-72.
6. Fujino Y., Guo X., Liu J., You L., Miyatake M., Yoshimura T. Mental health burden amongst inhabitants of an arsenic-affected area in Inner Mongolia, China. Soc. Sci. Med. 2004, 59:1969-1973. Japan Inner Mongolia Arsenic Pollution (JIAMP) Study Group.
7. Rodríguez V.M., Jiménez-Capdeville M.E., Giordano M. The effects of arsenic exposure on the nervous system. Toxicol. Lett. 2003, 145:1-18.
8. Sachdev P.S. Homocysteine and brain atrophy. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29:1152-1161.
9. Albrecht J., Sonnewald U., Waagepetersen H.S., Schousboe A. Glutamine in the central nervous system: function and dysfunction. Front. Biosci. 2007, 12:332-343.
10. de Koning T.J., Snell K., Duran M., Berger R., Poll-The B.T., Surtees R. l-Serine in disease and development. Biochem. J. 2003, 371:653-661.
11. Wu J.Y., Prentice H. Role of taurine in the central nervous system. J. Biomed. Sci. 2010, 17:S1-S6.
12. Johnston M.V. Neurotransmitters and vulnerability of the developing brain. Brain Dev. 1995, 17:301-306.
13. Johnston M.V., Ishiwa S. Ischemia and excitotoxins in development. Ment. Retard. Dev. Disabil. Res. Rev. 1995, 1:193-200.
14. Ikonomidou C., Bittigau P., Koch C., Genz K., Hoerster F., Felderhoff-Mueser U., Tenkova T., Dikranian K., Olney J.W. Neurotransmitters and apoptosis in the developing brain. Biochem. Pharmacol. 2001, 62:401-405.
15. Puka-Sundvall M., Gilland E., Bona E., Lehmann A., Sandberg M., Hagberg H. Development of brain damage after neonatal hypoxia-ischemia: excitatory amino acids and cysteine. Metab. Brain Dis. 1996, 11:109-123.
16. Cataltepe O., Towfighi J., Vannucci R.C. Cerebrospinal fluid concentrations of glutamate and GABA during perinatal cerebral hypoxia-ischemia and seizures. Brain Res. 1996, 709:326-330.
17. Puka-Sundvall M., Sandberg M., Hagberg H. Brain injury after hypoxia-ischemia in newborn rats: relationship to extracellular levels of excitatory amino acids and cysteine. Brain Res. 1997, 750:325-328.
18. Wallin C., Puka-Sundvall M., Hagberg H., Weber S.G., Sandberg M. Alterations in glutathione and amino acid concentrations after hypoxia-ischemia in the immature rat brain. Dev. Brain Res. 2000, 125:51-60.
19. Jin Y., Wang G., Zhao F., Liao Y., Sun D., Zhong Y., Yu X., Lv X., Li G., Sun G. Distribution of speciated arsenicals in mice exposed to arsenite at the early life. Ecotoxicol. Environ. Saf. 2010, 73:1323-1326.
20. Wang D., Zhang L., Jiang G. Application of analyzing amino acids by reserved-phase high performance liquid chromatography with DABS-Cl precolumn derivatization technique. Suzhou Univ. J. Med. Sci. 2003, 23:664-667.
21. Kang X., Xiao J., Huang X., Gu Z. Optimization of dansyl derivatization and chromatographic conditions in the determination of neuroactive amino acids of biological samples. Clin. Chim. Acta 2006, 366:352-356.
22. Clark D.L., Boutros N.N., Mendez M.F. The Brain and Behavior 2010, Cambridge University Press, pp. 21-22.
23. Cooper J.R., Bloom F.E., Roth R.H. The Biochemical Basis of Neuropharmacology 2003, Oxford University Press, New York.
24. Wang L.Z., Zhu X.Z. Serine racemase expression in mouse cerebral cortex after permanent focal cerebral ischemia. Acta Pharmacol. Sin. 2004, 25:436-441.
25. Herlenius E., Lagercrantz H. Neurotransmitters and neuromodulators during early human development. Early Hum. Dev. 2001, 65:21-37.
26. Qu C.Q., Niu Y.H., Zhong Y., Yu X.Y., Li G.X., Lv X.Q., Sun G.F., Jin Y.P. Effects of subchronic arsenic exposure on glutamate-glutamine cycle in mice brain. J. Environ. Health 2007, 24:751-754.
27. Mattson M.P., Shea T.B. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci. 2003, 26:137-146.
28. Gamble M.V., Liu X., Ahsan H., Pilsner R., Ilievski V., Slavkovich V., Parvez F., Levy D., Factor-Litvak P., Graziano J.H. Folate, homocysteine, and arsenic metabolism in arsenic-exposed individuals in Bangladesh. Environ. Health Perspect. 2005, 113:1683-1688.